SKB565 / Sichuan Kelun Pharma - LARVOL DELTA

SKB565 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor

SKB565 for Injection in Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=180 | Not yet recruiting | Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Trial completion date: May 2029 ➔ Aug 2029 | Initiation date: Jun 2026 ➔ Sep 2026 | Trial primary completion date: Dec 2028 ➔ Mar 2029

Trial completion date • Trial initiation date • Trial primary completion date • Oncology • Solid Tumor

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd…announced that it has received a clinical trial notice from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) approving the Investigational New Drug (IND) application for its novel dual-payload ADC drug, SKB565, for the treatment of advanced solid tumors. (PRNewswire)

New trial • Solid Tumor